Eileen M OReilly
Overview
Explore the profile of Eileen M OReilly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
328
Citations
12617
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Schleimer L, Aviki E, Kalvin H, Magnin J, Sokolowski S, Kingham T, et al.
JCO Oncol Pract
. 2024 Dec;
:OP2400528.
PMID: 39705655
Purpose: Financial toxicity (FT) is increasingly recognized as a major issue in cancer care. We evaluated the prevalence and risk factors for FT in patients with pancreatic ductal adenocarcinoma (PDAC)...
12.
Eikenboom E, Nasar N, Seier K, Gonen M, Spaander M, OReilly E, et al.
Ann Surg Oncol
. 2024 Dec;
PMID: 39656390
Background: Pancreatic ductal adenocarcinoma (PDAC) remains a challenging disease due to its aggressiveness, late-stage diagnosis, and limited treatment options. Microsatellite instability-high (MSI-H) cancers are susceptible to immune checkpoint inhibitors. Survival...
13.
Gelfer R, Gulla A, Kalvin H, Song Y, Harding J, Abou-Alfa G, et al.
JCO Precis Oncol
. 2024 Dec;
8:e2400263.
PMID: 39642327
Purpose: variants are associated with poor outcomes in biliary tract cancers (BTCs). This study assesses the prevalence of variants and their association with survival and recurrence in patients with intrahepatic...
14.
Cloyd J, Sarna A, Arango M, Bates S, Bhutani M, Bloomston M, et al.
JAMA Surg
. 2024 Dec;
160(2):172-180.
PMID: 39630427
Importance: Neoadjuvant therapy (NT) is an increasingly used treatment strategy for patients with localized pancreatic ductal adenocarcinoma (PDAC). Little research has been conducted on cancer care delivery during NT, and...
15.
Blair A, Radomski S, Chou J, Liu M, Howell T, Park W, et al.
Ann Surg Oncol
. 2024 Nov;
32(3):1869-1878.
PMID: 39576455
Background: Pancreatic acinar cell carcinoma (pACC) is a rare neoplasm of the exocrine pancreas. There is a dearth of information about tumor characteristics and patient outcomes. This study describes the...
16.
Jee J, Fong C, Pichotta K, Tran T, Luthra A, Waters M, et al.
Nature
. 2024 Nov;
636(8043):728-736.
PMID: 39506116
The digitization of health records and growing availability of tumour DNA sequencing provide an opportunity to study the determinants of cancer outcomes with unprecedented richness. Patient data are often stored...
17.
Keane F, OConnor C, Moss D, Chou J, Perry M, Crowley F, et al.
J Natl Cancer Inst
. 2024 Oct;
117(3):496-506.
PMID: 39460946
Background: Adjuvant modified leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin (FOLFIRINOX) is standard of care for fit individuals with resected pancreatic ductal adenocarcinoma (PDAC). Data are limited on adjuvant modified...
18.
Wainberg Z, OReilly E
Nat Rev Clin Oncol
. 2024 Oct;
21(12):900-901.
PMID: 39455872
No abstract available.
19.
Dekker E, Narayan R, Ahmami M, Meddouch A, Verkolf E, Gehrels A, et al.
Br J Surg
. 2024 Oct;
111(10).
PMID: 39400008
Background: Patients with localized (that is non-metastatic) pancreatic ductal adenocarcinoma with an inadequate response or toxicity to first-line chemotherapy may benefit from chemotherapy switch. The aim was to explore the...
20.
Chan J, Geyer S, Zemla T, Knopp M, Behr S, Pulsipher S, et al.
N Engl J Med
. 2024 Sep;
392(7):653-665.
PMID: 39282913
Background: Treatment options for patients with advanced neuroendocrine tumors are limited. The efficacy of cabozantinib in the treatment of previously treated, progressive extrapancreatic or pancreatic neuroendocrine tumors is unclear. Methods:...